Clinical trials: Depressive Disorder
Anxiety Disorders, Major Depressive Disorder
Study of Neuro-Cognitive Correlates of Pediatric Anxiety Disorders
Study Description: This study examines relations between neurocognitive and clinical features of pediatric anxiety disorders. The study uses neuro-cognitive tasks, functional magnetic resonance imaging (fMRI), as well as magneto…
- Trial name
- NCT00018057
- Testing
- Attention Bias Modification Training, Fluoxetine, Cognitive Behavioral Therapy
- Where
- 2 sites in United States
- Volunteers
- 3,500 people, healthy volunteers welcome
- Sponsor
- National Institute of Mental Health (NIMH)
Healthy Volunteer, Major Depressive Disorder
Neuropharmacologic Imaging and Biomarker Assessments of Response to Acute and Repeated-Dosed Ketamine Infusions in Major Depressive Disorder
Background: Most medications that treat depression take weeks or months to work. Researchers want to develop fast-acting treatments. One dose of ketamine has a rapid antidepressant effect.
- Conditions
- Healthy Volunteer, Major Depressive Disorder, Depression
- Trial name
- NCT03065335
- Testing
- Ketamine, Cobot TS MV robotic arm for TMS, NeurOptics PLRTM-30000 Pupillometer
- Where
- United States
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- National Institute of Mental Health (NIMH)
Depression
Characterization and Treatment of Adolescent Depression
This research study seeks to find causes and treatments of depression in teenagers. The study goals are to increase our knowledge of treatments for depression and understand how the brain changes when teenagers have depression.
- Trial name
- NCT03388606
- Testing
- Growth Mindset
- Where
- 3 sites in United States
- Volunteers
- 4,100 people, healthy volunteers welcome
- Sponsor
- National Institute of Mental Health (NIMH)
Major Depressive Disorder, Substance Use Disorder
Defining Neurobiological Links Between Substance Use and Mental Illness
Background: Nicotine dependence leads to about 480,000 deaths every year in the United States. People with major depressive disorder (MDD) are twice as likely to use nicotine compared to the general population.
- Conditions
- Major Depressive Disorder, Substance Use Disorder, Normal Physiology
- Trial name
- NCT05538910
- Testing
- Nicotine Patch
- Where
- United States
- Volunteers
- 620 people, healthy volunteers welcome
- Sponsor
- National Institute on Drug Abuse (NIDA)
Major Depressive Disorder
Study of ALTO-300 in MDD
The purpose of this study is to determine efficacy differences between ALTO-300 and placebo, used adjunctively to an antidepressant, related to patient characteristics.
- Trial name
- NCT05922878
- Testing
- ALTO-300
- Where
- 75 sites in United States
- Volunteers
- 325 people
- Sponsor
- Alto Neuroscience
Major Depressive Disorder
Psychopharmacotherapy for Depressive Patients
The primary purpose of this study is to compare the short (12 week) and long-term (1-year) efficacy and the tolerability between stepwise psychopharmacotherapy and antidepressant monotherapy for 12 weeks in adult patients with…
- Trial name
- BMDD-2022 (NCT06054321)
- Testing
- stepwise pharmacotherapy, antidepressant monotherapy group
- Where
- South Korea
- Volunteers
- 400 people
- Sponsor
- Chonnam National University Hospital
Treatment Resistant Depression, Autism Spectrum Disorder
Psilocybin for Treatment-Resistant Depression in Autism
We propose a first-of-its-kind open-label clinical trial to investigate the feasibility, tolerability, and safety of administering psilocybin in autistic adults with treatment-resistant depression (TRD).
- Trial name
- PAT-DA (NCT06731621)
- Testing
- Psilocybin
- Where
- Canada
- Volunteers
- 18 people
- Sponsor
- Centre for Addiction and Mental Health
Major Depressive Disorder (MDD), Alcohol Use Disorder (AUD)
Psilocybin-assisted Therapy for Comorbid Major Depressive Disorder and Alcohol Use Disorder
The goal of this clinical trial is to determine the safety and efficacy of psilocybin assisted Therapy (PAT) in individuals with comorbid Major Depressive Disorder (MDD) and Alcohol Use Disorder (AUD).
- Trial name
- NCT07405606
- Testing
- Psilocybin 25 mg
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- Centre for Addiction and Mental Health
Treatment-resistant Depression (TRD)
ALTO-207 in Adults With Treatment-resistant Depression (TRD)
The purpose of this trial is to measure depressive symptoms following treatment with ALTO-207 compared with placebo in participants with TRD.
- Trial name
- NCT07553637
- Testing
- ALTO-207
- Where
- 63 sites in United States, United Kingdom
- Volunteers
- 178 people
- Sponsor
- Alto Neuroscience
Depression / Major Depressive Disorder
Longitudinal Effects of Brain Stimulation on Decision-Making and Reward Learning
This study investigates the longitudinal effects of brain stimulation treatments on decision-making and reward learning. Here, daily assessments of reinforcement learning behavior are used in patients with depression who receive…
- Trial name
- NCT07823218
- Where
- Germany
- Volunteers
- 100 people
- Sponsor
- University of Bonn
Major Depression
Psilocybin for Depression in Veterans
More efficacious treatments for Major Depressive Disorder (MDD) in Veterans are urgently needed. Psilocybin is a promising novel treatment that is likely to be the first FDA-approved psychedelic, but its safety and efficacy…
- Trial name
- PACT (NCT07895134)
- Testing
- Psilocybin, modafinil, zolpidem
- Where
- 4 sites in United States
- Volunteers
- 150 people
- Sponsor
- VA Office of Research and Development
Major Depressive Disorder
NMDA Modulation in Major Depressive Disorder
Most of the current antidepressants for major depressive disorder (MDD) are based upon the monoamine hypothesis which cannot fully explain the etiology of depression.
- Trial name
- NCT04637620
- Testing
- NMDAE, Sertraline
- Where
- Taiwan
- Volunteers
- 90 people
- Sponsor
- China Medical University Hospital
Major Depressive Disorder
NMDA Modulation in Antidepressant Nonresponders With Major Depressive Disorder
Most of the current antidepressants for major depressive disorder (MDD) are based upon the monoamine hypothesis which cannot fully explain the etiology of depression.
- Trial name
- NCT05136755
- Testing
- NMDAE
- Where
- Taiwan
- Volunteers
- 50 people
- Sponsor
- China Medical University Hospital
Bipolar Disorder (BD), Major Depressive Diorder
Stress Management With Real-time Bio-signal Biofeedback
The goal of this clinical trial is to learn if the real-time bio-signal monitoring device (Neuronicle FX2 device), combined with mindfulness-based cognitive therapy (MBCT), helps manage stress and improves symptoms of mood…
- Trial name
- NCT06616116
- Testing
- Biosignal feedback
- Where
- South Korea
- Volunteers
- 140 people
- Sponsor
- Seoul National University Hospital
ASD, Autism Spectrum Disorder
Theta Burst Stimulation for Refractory Depression in Autism Spectrum Disorder
Evaluate the efficacy of accelerated theta burst stimulation (aTBS) in reducing depressive symptoms in autism spectrum disorder (ASD)
- Conditions
- ASD, Autism Spectrum Disorder, Autism, Depression - Major Depressive Disorder
- Trial name
- RETSORE-RCT (NCT06670040)
- Testing
- Transcranial Magnetic Stimulation
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Treatment Resistant Depression
InTRavenous kEtAmine and immerSive virtUal Reality to Treat dEpression
Depression is a common condition, with serious negative effects on the health and quality of life of those affected. While there are currently various medications which attempt to treat depression, they often take a long time to…
- Trial name
- TREASURE (NCT06781697)
- Testing
- Ketamine, Oculus VR headset
- Where
- Canada
- Volunteers
- 31 people
- Sponsor
- Sunnybrook Health Sciences Centre
Major Depression
Psilocybin Intervention for Veterans Overcoming Treatment-Resistant Depression
The purpose of this multi-site randomized controlled trial is to evaluate the efficacy and risks of psilocybin for the treatment of depression in U.S.
- Trial name
- PIVOT (NCT07226232)
- Testing
- Psilocybin
- Where
- 5 sites in United States
- Volunteers
- 240 people
- Sponsor
- VA Office of Research and Development
Treatment Resistant Depression, Substance Use Disorders
Psilocybin Assisted Psychotherapy for Treatment Resistant Depression and Co-occurring Substance Use Disorder
The goal of this clinical trial is to learn if a single dose of psilocybin (5mg Vs 10mg Vs 25mg) alongside psychotherapy is safe and can help treat treatment resistant depression (TRD) with co-occurring substance use disorder…
- Trial name
- NCT07499583
- Testing
- Psilocybin
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- Indiana University
Generalized Anxiety Disorder (GAD), Depressive and Anxiety Disorders
Miles for Mental Health
Common mental health disorders, like anxiety and depression, are widespread among the American population. The prevalence of mental health disorders among adults continues has consistently increased from previous decades and is…
- Trial name
- NCT07541443
- Testing
- Exercise
- Volunteers
- 20 people
- Sponsor
- Emporia State University
Major Depressive Disorder
A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend)
A Phase 3 Double-blind, Placebo-controlled Study (Part A) with an Open-label Extension (Part B) Evaluating DT120 Compared to Placebo in Major Depressive Disorder - Ascend
- Trial name
- NCT07592689
- Testing
- DT120
- Where
- 30 sites in United States
- Volunteers
- 165 people
- Sponsor
- Definium Therapeutics US, Inc.